The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals for innovative research on FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.
Grants of up to $150,000 will be awarded for research on the pathologic mechanisms underlying FTD. Priority will be given to projects related to the development and testing of novel high-throughput screening assays; identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept; and/or development and/or characterization of new model organisms or cellular models in support of drug-discovery efforts. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.
To be eligible, applicants must be an academic investigator seeking to create and support innovative translational programs in an academic medical center, university, or biotechnology company with programs dedicated to neurodegenerative disease translational development. New biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding also are eligible to apply.
Letters of Intent must be received no later than July 31, 2017. Upon review, selected applicants will be invited to submit a full proposal by September 8, 2017.
See the ADDF website for complete program guidelines and application instructions.